ArTS Archivio della ricerca di Trieste

ROCCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.433
AS - Asia 3.044
EU - Europa 1.441
SA - Sud America 551
Continente sconosciuto - Info sul continente non disponibili 236
AF - Africa 75
OC - Oceania 1
Totale 8.781
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.279
SG - Singapore 1.071
CN - Cina 632
IT - Italia 576
BR - Brasile 412
HK - Hong Kong 361
VN - Vietnam 293
KR - Corea 239
BD - Bangladesh 146
DE - Germania 117
FR - Francia 110
SE - Svezia 102
NL - Olanda 97
IN - India 88
CA - Canada 75
GB - Regno Unito 72
RU - Federazione Russa 70
CH - Svizzera 69
PL - Polonia 57
FI - Finlandia 42
AR - Argentina 41
MX - Messico 35
TW - Taiwan 32
CO - Colombia 25
ID - Indonesia 25
IE - Irlanda 25
EC - Ecuador 23
MA - Marocco 22
AT - Austria 20
TR - Turchia 19
IQ - Iraq 18
CL - Cile 16
ES - Italia 15
AE - Emirati Arabi Uniti 14
JP - Giappone 14
PH - Filippine 14
UA - Ucraina 13
PK - Pakistan 12
PY - Paraguay 12
SA - Arabia Saudita 12
VE - Venezuela 11
CR - Costa Rica 10
TH - Thailandia 9
UZ - Uzbekistan 9
EG - Egitto 8
IR - Iran 8
KE - Kenya 8
RO - Romania 8
SN - Senegal 8
BE - Belgio 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
ZA - Sudafrica 7
BG - Bulgaria 6
DZ - Algeria 6
JM - Giamaica 6
LT - Lituania 5
AL - Albania 4
CZ - Repubblica Ceca 4
GT - Guatemala 4
XK - ???statistics.table.value.countryCode.XK??? 4
AZ - Azerbaigian 3
BO - Bolivia 3
GE - Georgia 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
IL - Israele 3
JO - Giordania 3
MY - Malesia 3
NI - Nicaragua 3
NO - Norvegia 3
PT - Portogallo 3
SI - Slovenia 3
SV - El Salvador 3
TN - Tunisia 3
BS - Bahamas 2
CI - Costa d'Avorio 2
DK - Danimarca 2
ET - Etiopia 2
NP - Nepal 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AU - Australia 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BZ - Belize 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
HT - Haiti 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 8.538
Salva come PNG Salva come JPEG
Città #
Singapore 595
Ashburn 587
Hong Kong 356
San Jose 347
Council Bluffs 277
Hefei 247
Seoul 234
Boardman 159
Beijing 154
Dallas 112
Santa Clara 110
Ho Chi Minh City 100
Trieste 88
Milan 87
Columbus 86
Los Angeles 74
Chicago 67
New York 66
Bern 59
Hanoi 59
Lauterbourg 54
São Paulo 46
Buffalo 41
Zgierz 38
Princeton 35
Rome 34
Phoenix 33
The Dalles 33
Frankfurt am Main 31
Moscow 31
London 28
Memphis 27
Taipei 27
Houston 25
Seattle 25
Dublin 24
Helsinki 22
North Bergen 22
Pune 21
Nuremberg 20
Atlanta 17
Orem 17
Redondo Beach 17
Toronto 17
Brasília 16
Montreal 16
Düsseldorf 15
Fairfield 15
Lappeenranta 15
Miano 15
Munich 15
Rio de Janeiro 15
Boydton 14
Denver 14
Amsterdam 13
Chennai 13
Shanghai 13
Quito 12
Warsaw 12
Naples 11
Philadelphia 11
Stockholm 11
Tappahannock 11
Casablanca 10
Chandler 10
Treviso 10
Dhaka 9
Haiphong 9
Hangzhou 9
Madrid 9
San Francisco 9
Vienna 9
Washington 9
Wilmington 9
Woodbridge 9
Ankara 8
Da Nang 8
Dakar 8
Jacksonville 8
Las Vegas 8
San Donà di Piave 8
San José 8
Santiago 8
Tashkent 8
Bologna 7
Brooklyn 7
Brussels 7
Cleveland 7
Jakarta 7
Tokyo 7
Apodaca 6
Asunción 6
Biên Hòa 6
Can Tho 6
Duino-Aurisina 6
Itaquaquecetuba 6
Kingston 6
Manchester 6
Shenzhen 6
Torviscosa 6
Totale 5.091
Salva come PNG Salva come JPEG
Nome #
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 216
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial 212
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 208
179 C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 203
A tailored machine learning approach for mortality prediction in severe COVID-19 treated with glucocorticoids 193
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT 188
Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients 172
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 165
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets 157
Ribociclib and Endocrine Therapy in Breast Cancer 132
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer 119
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 117
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study 117
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 114
Can Systems Biology Advance Clinical Precision Oncology? 113
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 110
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 109
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 108
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 107
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer 104
Androgen receptor signaling pathways as a target for breast cancer treatment 102
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 102
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses 101
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer 101
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy 101
Early C-reactive protein reduction predicts survival in COVID-19 severe pneumonia treated with glucocorticoids 99
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ 99
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 99
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study 98
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer 97
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial 96
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 93
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 92
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer 92
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemo-immunotherapy in patients with advanced melanoma 92
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 91
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype 89
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression 89
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy 88
[Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine] 87
Precision medicine: PI3K targeting in advanced breast cancer 87
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer 87
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 86
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer 85
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 85
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas 85
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience 84
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 84
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 84
A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer 82
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer 82
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 81
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 81
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 80
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 80
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy 79
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis 77
Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer 77
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. A case report 76
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels 76
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients 72
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 72
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 68
Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study 62
Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies 60
Existence and relevance of fulminant severe community-acquired pneumonia 57
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 55
Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients 54
The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings 53
Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? 52
CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience 50
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer 50
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel 45
Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients 44
Virtual Biomarkers and Simplified Metrics in the Modeling of Breast Cancer Neoadjuvant Therapy: A Proof-of-Concept Case Study Based on Diagnostic Imaging 44
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 43
Circulating tumor cells in early breast cancer: A connection with vascular invasion 41
Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer 40
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 39
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence 39
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects 38
Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course 38
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer 37
Radiotherapy, morphine, and bone pain: a difficult relationship? 35
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy 35
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer 35
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer 34
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review 34
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer 34
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy 34
CTCs in early breast cancer: A path worth taking 33
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer 33
Diagnosis and management of neck metastases from an unknown primary 33
Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients 32
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy 31
Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience 31
Update: current management issues in malignant melanoma 31
Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results 31
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer? 30
Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer 30
Totale 8.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.192
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.192
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202250 0 0 0 0 0 1 0 2 1 14 3 29
2022/2023470 16 2 9 19 32 65 2 100 101 8 95 21
2023/2024701 89 43 32 63 63 54 92 112 20 35 65 33
2024/20251.950 19 167 308 104 157 114 226 88 265 172 121 209
2025/20264.582 401 483 317 304 259 273 493 120 506 682 393 351
2026/2027949 276 355 318 0 0 0 0 0 0 0 0 0
Totale 8.781